+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target



Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target



Current Opinion in Cardiology 24(4): 358-363



Lipoprotein-associated phospholipase A2 (Lp PLA2) is postulated to occupy a key position in the pathogenic sequence leading to formation of complex atherosclerotic lesions. This study reviews evidence supporting its role as a biomarker of vascular disease and as a possible therapeutic target. Evidence continues to build supporting the usefulness of Lp PLA2 as a predictor of coronary events in the general population and in those with established coronary heart disease. Elevated Lp PLA2 is also associated with stroke and heart failure. The crystal structure of Lp PLA2 is now available and offers insight into the links between structure, function and atherogenic properties. Recently completed studies on the efficacy of darapladib, a specific Lp PLA2 inhibitor, show beneficial changes in plaque morphology in animal models and in humans. Lp PLA2 is gaining acceptance as a useful biomarker of chronic inflammation and as a predictor of vascular disease. Early results with darapladib offer promise, but not definitive proof, of a potential role for Lp PLA2 inhibition in coronary heart disease prevention.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054139414

Download citation: RISBibTeXText

PMID: 19417639

DOI: 10.1097/hco.0b013e32832bcb22


Related references

Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Current Opinion in Pharmacology 1(2): 121-125, 2001

Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Review of Molecular Diagnostics 7(5): 511-517, 2007

Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. Journal of the American Heart Association 5(6):, 2016

The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. Journal of the American College of Cardiology 51(17): 1632-1641, 2008

Lipoprotein-associated phospholipase A2: how effective as a risk marker of cardiovascular disease and as a therapeutic target?. Inflammation and Allergy Drug Targets 10(4): 236-246, 2011

Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease. Current Pharmaceutical Design 24(3): 291-296, 2018

Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine 343(16): 1148-1155, 2000

Lipoprotein-associated phospholipase A2 and aortic stenosis: biomarker or new target for an old foe?. Jacc. Cardiovascular Imaging 8(1): 34-36, 2015

Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. New England Journal of Medicine 343(16): 1148-1155, 2000

Lipoprotein-associated phospholipase A2 in coronary heart disease: Review and meta-analysis. Clinica Chimica Acta; International Journal of Clinical Chemistry 465: 22-29, 2017

Heart rate as a therapeutic target after acute coronary syndrome and in chronic coronary heart disease. Giornale Italiano di Cardiologia 18(3 Suppl 1): 3s, 2017

Study on the correlation between the concentration of plasma lipoprotein-associated phospholipase A2 and coronary heart disease. Chronic Diseases and Translational Medicine 1(2): 105-109, 2015

Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes. Diabetes 59(5): 1239-1243, 2010

An association study between genetic polymorphisms related to lipoprotein-associated phospholipase A(2) and coronary heart disease. Experimental and Therapeutic Medicine 5(3): 742-750, 2013

Lipoprotein-associated phospholipase A 2 , and subsequent cardiovascular events and mortality among patients with coronary heart disease. Biomarkers 22(3-4): 219-224, 2016